首页|期刊导航|广东医学|基线非小细胞肺癌组织CD8+TILs及SII对免疫治疗的预后价值

基线非小细胞肺癌组织CD8+TILs及SII对免疫治疗的预后价值OA

Prognostic value of baseline CD8+tumor-infiltrating lymphocytes and systemic immune-inflammation index in non-small cell lung cancer patients receiving immunotherapy

中文摘要英文摘要

目的 如何筛选可靠的免疫治疗预后生物标志物预测免疫检查点抑制剂(ICIs)治疗初诊不可切除驱动基因阴性非小细胞肺癌(NSCLC)仍是目前研究热点.该研究分析NSCLC基线肿瘤组织CD8+肿瘤浸润淋巴细胞(CD8+TILs)的表达及系统性免疫炎症指数(SII)在免疫治疗中的预后价值,探索联合检测CD8+TILs及SII成为预测免疫治疗疗效生物标志物的意义.方法 回顾性分析2018年1月1日至2022年12月31日期间华南理工大学附属第六医院收治的78例Ⅲ~Ⅳ期的驱动基因阴性NSCLC初诊接受免疫治疗患者,收集治疗前石蜡组织标本及血液检查结果作为基线,免疫组织化学方法检查肿瘤组织CD8+TILs的表达密度,SII由血小板数量×中性粒细胞数量/淋巴细胞数量计算得出.随访至2023年12月31日,观察生存期为主要终点,以中位数分CD8+TILs高低表达组、SII高低表达两组;采用x2检验或Fisher确切概率法分析CD8+TILs及SII表达亚组之间与临床病理特征的相关关系.Kaplan-Meier生存曲线分析CD8+TILs及SII表达分组NSCLC的无进展生存期(PFS)、总生存期(OS).单因素COX回归分析临床特征与PFS、OS的相关关系,多变量Cox回归分析确定SII及CD8+TILs表达为NSCLC免疫治疗的独立危险因素.结果 78例NSCLC患者mPFS为4.9个月,mOS为10.2个月.两组NSCLC患者的年龄、性别、体重指数(BMI)、吸烟史、TNM分期差异均无统计学意义(P均>0.05).Kaplan-Meier生存曲线显示,高、低水平CD8+TILs NSCLC组的mPFS分别为18.867个月、8.067个月(P=0.076),高CD8+TILs组NSCLC患者的mOS明显长于低CD8+TILs组(P=0.028);高、低水平SII组NSCLC患者的mPFS分别为8.367个月、18.867个月(P=0.354),低SII组患者的中位OS未达到但显著长于高SII组(28.03个月)(95%CI:14.09~41.97,P=0.040).依据CD8+TILs+及SII表达组合分为4组,高CD8+TILs+低SII组NSCLC患者的mOS最长,较低CD8+TILs+高SII组显著延长(P=0.004).单因素回归分析,高CD8+TILs组NSCLC患者的PFS比低CD8+TILs 组长(HR=0.420,95%CI:0.184~0.958,P=0.039);非吸烟者的 OS 比吸烟者长(HR=4.385,95%CI:1.363~14.102,P=0.013),NSCLC 患者 CD8+TILs 高水平组较低水平组的 OS 更长(HR=0.187,95%CI:0.055~0.631,P=0.007),吸烟史和CD8+TILs水平与NSCLC患者的OS存在显著关系.多因素COX回归分析显示,高水平 CD8+TILs 与更长的 PFS(HR=0.477,95%CI:0.229~0.992,P=0.048)和 OS(HR=0.306,95%CI:0.106~0.880,P=0.028)相关,低 SII 与更长的 OS(HR=3.114,95%CI:1.065~9.107,P=0.038)相关,CD8+TILs和SII是影响免疫治疗预后的独立预后因素.结论 驱动基因阴性晚期NSCLC患者治疗前CD8+肿瘤浸润淋巴细胞(TIL)高水平表达,低SII评分与免疫治疗的预后正相关;CD8+TILs和SII是影响NSCL免疫治疗预后的独立预后因素,联合检测CD8+TILs水平与SII评分能有效区分免疫治疗亚组,较单一因素能更有效评估预后,有望成为免疫治疗预测生物标志物,为临床NSCLC综合治疗改善肿瘤免疫微环境从而改善免疫治疗预后提供理论依据.

Objective To identify reliable prognostic biomarkers for predicting the efficacy of immune checkpoint inhibitors(ICIs)in patients with newly diagnosed,unresectable,driver gene-negative non-small cell lung cancer(NSCLC)remains an important area of research.This study investigated the prognostic value of baseline CD8+tumor-infiltrating lymphocytes(CD8+TILs)and the systemic immune-inflammation index(SII)in NSCLC patients receiving immunotherapy,and explored the potential value of their combined assessment as a biomarker for predicting the efficacy of immunotherapy.Methods A retrospective analysis was conducted in 78 patients with newly diagnosed stage Ⅲ-Ⅳ driver gene-negative NSCLC who received immunotherapy at The Sixth Affiliated Hospital of South China University of Technology from January 1,2018,to December 31,2022.Pretreatment paraffin-embedded tumor tissue specimens and blood test results were collected as baseline data.The density of CD8+TILs in tumor tissues was assessed by immunohis-tochemistry.The SII was calculated as platelet count × neutrophil count/lymphocyte count.Patients were followed up un-til December 31,2023,with survival as the primary endpoint.Patients were divided into high-and low-expression groups according to the median levels of CD8+TILs and SII.The associations of CD8+TILs and SII expression with clini-copathological characteristics were analyzed using the chi-square test or Fisher's exact test.Kaplan-Meier survival anal-ysis was performed to evaluate progression-free survival(PFS)and overall survival(OS)according to CD8+TILs and SII levels.Univariate Cox regression analysis was used to assess the associations between clinical characteristics and PFS or OS,and multivariate Cox regression analysis was performed to identify independent prognostic factors associated with immunotherapy outcomes.Results Results Among the 78 patients with NSCLC,the median PFS(mPFS)was 4.9 months and the median OS(mOS)was 10.2 months.No statistically significant differences were observed between the two groups in terms of age,sex,body mass index(BMI),smoking history,histological type,or TNM stage(all P>0.05).Kaplan-Meier survival analysis showed that the mPFS was 18.867 and 8.067 months in patients with high and low CD8+TILs lev-els,respectively(P=0.076),whereas the mOS was significantly longer in the high-CD8+TILs group than in the low-CD8+TILs group(P=0.028).The mPFS was 8.367 and 18.867 months in the high-and low-SII groups,respectively(P=0.354).The median OS was not reached in the low-SII group and was significantly longer than that in the high-SII group,which was 28.03 months(95%CI:14.09-41.97;P=0.040).According to the combined expression levels of CD8+TILs and SII,patients were divided into four groups.Patients with high CD8+TILs levels and low SII had the longest mOS,which was significantly longer than that in patients with low CD8+TILs levels and high SII(P=0.004).Univariate Cox regression analysis showed that patients with high CD8+TILs levels had longer PFS than those with low CD8+TILs levels(HR=0.420,95%CI:0.184-0.958;P=0.039).Non-smokers had longer OS than smokers(HR=4.385,95%CI:1.363-14.102;P=0.013),and patients with high CD8+TILs levels had longer OS than those with low CD8+TILs levels(HR=0.187,95%CI:0.055-0.631;P=0.007).Smoking history and CD8+TILs level were significantly associated with OS.Multivariate Cox regression analysis showed that a high CD8+TILs level was associated with longer PFS(HR=0.477,95%CI:0.229-0.992;P=0.048)and OS(HR=0.306,95%CI:0.106-0.880;P=0.028),whereas a low SII was associated with longer OS(HR=3.114,95%CI:1.065-9.107;P=0.038).CD8+TILs and SII were independent prognostic factors associated with immunotherapy outcomes.Conclusion In pa-tients with advanced driver gene-negative NSCLC,a high baseline level of CD8+TILs and a low SII before treatment are associated with more favorable outcomes following immunotherapy.CD8+TILs and SII are independent prognostic factors associated with immunotherapy outcomes in NSCLC.The combined assessment of CD8+TILs levels and SII may effectively distinguish prognostic subgroups among patients receiving immunotherapy and may provide greater prognostic information than either factor alone.These findings suggest that the combination of CD8+TILs and SII may serve as a potential bio-marker for predicting immunotherapy outcomes and may provide a theoretical basis for improving the tumor immune micro-environment and immunotherapy outcomes through comprehensive treatment of NSCLC.

唐武兵;陈健智;潘兴喜;袁燕玲;童丽华;杨文;李漫杰

华南理工大学附属第六医院(佛山市南海区人民医院)肿瘤医学中心(广东佛山 528200)华南理工大学附属第六医院(佛山市南海区人民医院)病理科(广东佛山 528200)华南理工大学附属第六医院(佛山市南海区人民医院)肿瘤医学中心(广东佛山 528200)华南理工大学附属第六医院(佛山市南海区人民医院)肿瘤医学中心(广东佛山 528200)华南理工大学附属第六医院(佛山市南海区人民医院)肿瘤医学中心(广东佛山 528200)华南理工大学附属第六医院(佛山市南海区人民医院)肿瘤医学中心(广东佛山 528200)华南理工大学附属第六医院(佛山市南海区人民医院)肿瘤医学中心(广东佛山 528200)

医药卫生

非小细胞肺癌免疫治疗肿瘤免疫微环境CD8+肿瘤浸润淋巴细胞炎性指标

non-small cell lung cancerimmunotherapytumor immune microenvironmentCD8+tumor-in-filtrating lymphocytesinflammatory markers

《广东医学》 2026 (9)

1298-1309,12

国家卫生健康委重点课题(GWJJMB202510022014)白求恩公益基金会(z11caxw-07)华南理工大学附属第六医院面上项目(A2022001)

10.13820/j.cnki.gdyx.20261855

评论